01What it sells and who buys it
Chai provides AI models and software for designing therapeutic molecules and antibodies. Its buyers are pharmaceutical research organizations seeking more effective candidate design.
02How the business makes money
Commercial routes include platform licenses and research collaborations. Announced 2026 relationships include a Pfizer license and collaborations with Novartis and argenx; individual contract payments were not disclosed.
03Marketing and customer acquisition
Chai used experimental evidence and pharmaceutical platforms to reach research buyers.
- 01
Target the efficiency of molecular design
SourceThe offer supports antibody and therapeutic design. Buyers evaluate experimentally useful candidates, not merely visually convincing generated structures.
- 02
How distribution and adoption expanded
SourcePublished research and experimental results give scientists evidence to evaluate the technology. Lilly's TuneLab provides a route for participating biotechs to test its models. Major pharmaceutical relationships create reference deployments for expansion into other research organizations.
- 03
Financing the next stage
SourceA $130 million Series B in December 2025 was followed by a $400 million Series C at a $3.8 billion valuation in July 2026. Investors included Index Ventures, Kleiner Perkins, Sequoia and Dimension.
How the growth mechanism works
- Publish research results
- Validate experimentally
- Trial through a partner platform
- Expand research contracts
Lilly’s TuneLab provides an evaluation route. Research announcements and paid contracts are different stages; value depends on the total cost and time of designing and validating candidates.
04Funding and expansion
A $130 million Series B in December 2025 was followed by a $400 million Series C at a $3.8 billion valuation in July 2026. Investors included Index Ventures, Kleiner Perkins, Sequoia and Dimension.